| pubmed-article:19735056 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19735056 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19735056 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:19735056 | lifeskim:mentions | umls-concept:C0001047 | lld:lifeskim |
| pubmed-article:19735056 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19735056 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:19735056 | pubmed:issue | 4 Pt 2 | lld:pubmed |
| pubmed-article:19735056 | pubmed:dateCreated | 2009-12-9 | lld:pubmed |
| pubmed-article:19735056 | pubmed:abstractText | Poor response to antipsychotics is still an important problem in the treatment of many schizophrenia patients. N-acetylcysteine (NAC) is a compound that exerts anti-oxidant and scavenging actions against reactive oxygen species. This paper reports a case of poorly responsive schizophrenia patient who improved considerably with add-on NAC 600 mg/day. The NAC might work through activating cysteine-glutamate antiporters or reducing in nitric oxide (NO) metabolites, free radicals and cytokines or through both of these mechanisms. | lld:pubmed |
| pubmed-article:19735056 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19735056 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19735056 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19735056 | pubmed:issn | 1814-1412 | lld:pubmed |
| pubmed-article:19735056 | pubmed:author | pubmed-author:SavasHaluk... | lld:pubmed |
| pubmed-article:19735056 | pubmed:author | pubmed-author:ViritOsmanO | lld:pubmed |
| pubmed-article:19735056 | pubmed:author | pubmed-author:AltindagAbdur... | lld:pubmed |
| pubmed-article:19735056 | pubmed:author | pubmed-author:BulutMahmutM | lld:pubmed |
| pubmed-article:19735056 | pubmed:author | pubmed-author:DalkilicAlica... | lld:pubmed |
| pubmed-article:19735056 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19735056 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:19735056 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19735056 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19735056 | pubmed:pagination | 626-8 | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:meshHeading | pubmed-meshheading:19735056... | lld:pubmed |
| pubmed-article:19735056 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19735056 | pubmed:articleTitle | Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. | lld:pubmed |
| pubmed-article:19735056 | pubmed:affiliation | Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey. | lld:pubmed |
| pubmed-article:19735056 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19735056 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19735056 | lld:pubmed |
